They further showed that CD14+ PBMCs from lupus patients possessed elevated miR‐148a levels and enhanced osteoclastogenesis capacity, which may contribute to the lower BMD in lupus patients compared with normal controls. This evidence concerns the gene CD14 and systemic lupus erythematosus.